Cre/lox-assisted non-invasive in vivo tracking of specific cell populations by positron emission tomography

Martin Thunemann, Barbara F. Schörg, Susanne Feil, Yun Lin, Jakob Voelkl, Matthias Golla, Angelos Vachaviolos, Ursula Kohlhofer, Leticia Quintanilla-Martinez, Marcus Olbrich, Walter Ehrlichmann, Gerald Reischl, Christoph M. Griessinger, Harald F. Langer, Meinrad Gawaz, Florian Lang, Michael Schäfers, Manfred Kneilling, Bernd J. Pichler & Robert Feil

Many pathophysiological processes are associated with proliferation, migration or death of distinct cell populations. Monitoring specific cell types and their progeny in a non-invasive, longitudinal and quantitative manner is still challenging. Here we show a novel cell-tracking system that combines Cre/lox-assisted cell fate mapping with a thymidine kinase (sr39tk) reporter gene for cell detection by positron emission tomography (PET). We generate Rosa26-mT/sr39tk PET reporter mice and induce sr39tk expression in platelets, T lymphocytes or cardiomyocytes. As proof of concept, we demonstrate that our mouse model permits longitudinal PET imaging and quantification of T-cell homing during inflammation and cardiomyocyte viability after myocardial infarction. Moreover, Rosa26-mT/sr39tk mice are useful for whole-body characterization of transgenic Cre mice and to detect previously unknown Cre activity. We anticipate that the Cre-switchable PET reporter mice will be broadly applicable for non-invasive long-term tracking of selected cell populations in vivo.
Tracking cells non-invasively in vivo by molecular imaging allows the observation of cell behavior in health and disease. In addition to its importance for basic research, cell tracking has many potential applications in regenerative and individualized medicine and it facilitates the development of new diagnostic tools and therapeutic strategies. Numerous imaging techniques are used to visualize cells in vivo, including ultrasound, optical imaging, magnetic resonance imaging (MRI) and positron emission tomography (PET). These methods require conceptually different labeling and detection strategies that each have inherent advantages and disadvantages. Direct cell labeling makes use of radioactive, fluorescent or paramagnetic compounds, which are, however, eventually washed out and get diluted. Thus, longitudinal and quantitative monitoring of cells becomes challenging. In contrast, strategies based on stable expression of a chromosomally integrated reporter transgene permit long-term labeling of cells and their progeny.

The Cre/lox recombination system has emerged as a powerful tool to generate time- and tissue-specific mouse mutants. In addition, this technology can be used to genetically label specific cell populations to map their fate during development or in adult mice in the context of physiological or pathophysiological processes. For genetically inducible fate mapping, cell-type-specific expression of the tamoxifen-inducible CreER2 recombinase is combined with Cre-activatable reporter transgenes that are driven by ubiquitous promoters. With this approach, stable, inheritable reporter gene expression can be achieved in a distinct cell population labeled by Cre recombination at a predetermined time. Cre reporter transgenes encoding histochemical, fluorescent or bioluminescent reporter proteins have been integrated into the murine Rosa26 (R26) locus, which is accessible to the transcriptional machinery in most if not all cell types. With the currently available R26 Cre reporter mouse lines, however, non-invasive quantitative detection of labeled cells in vivo at the whole-body level is not possible, because detection of the aforementioned reporter proteins relies on either ex vivo methods requiring tissue fixation, invasive methods with a small field of view such as intravital microscopy, or semi-quantitative non-invasive methods such as bioluminescence imaging.

PET is a powerful non-invasive imaging modality in both preclinical and clinical settings. It has a high sensitivity and generates quantitative data, and recent advances in PET-MRI scanner technology enable simultaneous acquisition of functional and morphological information from living mice. Reporter genes for detection of cells by PET cause the accumulation of radiolabeled probes on or in reporter gene-expressing cells. One such PET reporter gene is the herpes simplex virus type 1 thymidine kinase (HSV1-tk). It is used in combination with 18F- or 124I-labeled nucleoside analogues, which are phosphorylated by HSV1-tk, but not by mammalian thymidine kinases. In their non-phosphorylated form, PET tracer sequences such as 9-(4-[18F]-Fluoro-3-[hydroxymethyl]butyl)guanine are “cell-permeable”, but after phosphorylation by HSV1-tk they are retained inside the cells. HSV1-tk or an improved variant that enables PET with 18F has been described to date. In such a mouse line, Cre-expressing cell populations will be labeled for PET imaging through Cre-mediated activation of reporter gene expression at the genomic level. Once reporter gene expression is activated, cells and their progeny are stably labeled, even if the cells proliferate or change their phenotype, which may lead to a loss of Cre expression. This approach would permit non-invasive long-term visualization of any given cell population for which a respective cell type-specific Cre mouse line is available.

To improve cell tracking in mammals, we generated R26 knock-in mice carrying a transgene for Cre-inducible sr39tk expression under control of the ubiquitous cytomegalovirus early enhancer/chicken β-actin/γ-globin (CAG) promoter. As these mice express membrane-targeted tandem-dimer tomato red fluorescent protein (mT) before Cre recombination and sr39tk after Cre recombination, we named them “R26-mT/sr39tk” mice. In these mice, a cell population of interest is labeled by Cre-dependent activation of sr39tk expression and then the fate of these cells is followed by non-invasive PET imaging with [18F]FHBG. As proof of concept, we demonstrate that the new R26-mT/sr39tk reporter mice enable cell type-specific longitudinal PET imaging of T-cell homing during tissue inflammation and of cardiomyocytes after myocardial infarction (MI). Furthermore, the Cre-responsive PET reporter allele permits non-invasive whole-body characterization of transgenic Cre mouse lines.

Results

Generation of R26-mT/sr39tk mice. We integrated the R26-mT/ sr39tk PET reporter construct by homologous recombination into the R26 locus of murine embryonic stem (ES) cells. Before Cre recombination, mT is expressed from the L1 allele, where “L2” stands for “two loxP sites”. In Cre-expressing cells, Cre recombination removes the mT-expressing encoding cassette and thereby activates sr39tk expression from the resulting L1 allele (“L1” stands for one loxP site) (Fig. 1 and Supplementary Fig. 1a). Cre-mediated activation of sr39tk expression in ES cells was confirmed at multiple levels: at the DNA level by Southern blot analysis (Supplementary Fig. 1b), at the protein level by western blot analysis (Supplementary Fig. 1c), and at the functional level by testing the sensitivity of the cells to the sr39tk suicide substrate ganciclovir (Supplementary Fig. 1d), as well as by measuring uptake of the PET tracer [18F]FHBG into the cells (Supplementary Fig. 1e). ES cells carrying the Cre-responsive L2 allele were used to establish the R26-mT/sr39tk mouse line. In line with previous publications, which used the same targeting vector but different reporter genes, we observed strong and ubiquitous mT expression in organs isolated from R26-mT/sr39tk mice (Supplementary Fig. 1f). The general appearance and viability of R26-mT/sr39tk mice (genotype: R26[sr39tk/+]), where “+” denotes the wild-type allele) was normal. However, male R26-mT/sr39tk mice showed severely reduced fertility. Male infertility has been described for some other HSV1-tk transgenic mouse lines and is presumably caused by HSV1-tk expression from a cryptic promoter located in the HSV1-tk coding region that is active in postmeiotic germ cells leading to impaired sperm development.

Detection of sr39tk-expressing cell populations by PET. We mated R26-mT/sr39tk mice with Pf4-Cre, CD4-Cre or Myh6-Cre mice with Cre[+/+] genotype (where “+” denotes the wild-type allele) to induce expression of sr39tk in platelets, T lymphocytes or cardiomyocytes, respectively (Fig. 1a and Supplementary Table 1). Animals carrying tissue-specific Cre and R26-mT/ sr39tk transgenes are denoted “Cre promoter/sr39tk” mice. We performed in vivo [18F]FHBG-PET imaging studies (Fig. 2) with Cre-positive experimental mice that were expected to express sr39tk in the respective target cells (sr39tk+; genotype: Cre[+/+], R26[sr39tk/+]). To evaluate nonspecific tracer uptake, Cre-negative control animals (sr39tk−; genotype: Cre[−/−], R26[sr39tk/−]) were...
analyzed in parallel. To allocate PET signals to anatomical structures, some animals underwent MRI. In addition to in vivo imaging, \[^{18}F\]FHBG uptake was assessed ex vivo via autoradiography and biodistribution analysis of selected organs (Fig. 3). To validate results obtained with R26-mT/sr39tk PET reporter mice, we tested all Cre transgenes with the well-established R26-lacZ Cre reporter line 10. LacZ-expressing mice (lacZ+; genotype: Cre[+/+],R26[lacZ/+] or Cre[−/−],R26[lacZ/−]) are denoted “Cre promoter/lacZ” mice. These were used to detect Cre-mediated activation of β-galactosidase expression by 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal) staining of fixed tissues. Cre-negative mice (lacZ−; genotype: Cre[+/+],R26[lacZ/+]) were used as negative controls for X-Gal staining (Supplementary Fig. 2 and 3).

In Pf4/sr39tk mice for visualization of platelets, we observed strong \[^{18}F\]FHBG accumulation in the spleen and weaker but still significant tracer uptake in lung and skeletal muscle (Fig. 2a, d left). Ex vivo analyses confirmed significant tracer accumulation in spleen, lungs and skeletal muscle, and, in addition, revealed sr39tk reporter gene activity in bone marrow and blood (Fig. 2a, d right). The activity of the Pf4-Cre transgene in cells of bone marrow, blood and spleen was also demonstrated by detection of β-galactosidase-positive cells in Pf4/lacZ mice (Supplementary Fig. 2a–c). Together, these results indicated that the PET signal observed in organs of Pf4/sr39tk mice, including signals in lung and skeletal muscle, were indeed derived from megakaryocytes and blood-borne platelets. In agreement with previous reports, nonspecific accumulation of background radioactivity was observed in the gastrointestinal tract 23 as well as in bone 26 of sr39tk+/− and sr39tk− animals (Fig. 2a–c).

CD4/sr39tk mice for T-cell tracking studies showed specific \[^{18}F\]FHBG uptake in the spleen, lymph nodes and thymus, and, unexpectedly, in the heart and lung (Figs. 2b, d middle and 3b, e). The PET signal observed in the spleen of CD4/sr39tk mice was significantly stronger than in sr39tk− control mice, but weaker than in Pf4/sr39tk mice (Figs 2d and 3d, e). In line with these results, CD4/lacZ mice demonstrated β-galactosidase activity in lymphatic organs (Supplementary Fig. 2d–f) as well as in heart and lung (Supplementary Fig. 2g, h). Closer inspection of X-Gal-stained tissue sections and immunostaining of marker proteins indicated previously unknown ectopic activity of the CD4-Cre transgene in smooth muscle cells of medium-caliber vessels of the heart (Supplementary Fig. 3a, b) as well as in bronchial epithelial cells of the lung and alveolar macrophages (Supplementary Fig. 3c–f). Ectopic activity of the CD4-Cre line in some vascular smooth muscle cells could also explain the weak but significant tracer uptake that was detected ex vivo in skeletal muscle (Fig. 3e).
In Myh6/sr39tk mice for detection of cardiomyocytes, in vivo PET imaging (Fig. 2c, d right) as well as ex vivo analysis of tissues (Fig. 3c, f) revealed strong $^{18}$F]FHBG uptake in the heart and, to a much smaller extent, in the lungs. These results were confirmed in Myh6/lacZ mice, which showed β-galactosidase activity in cardiomyocytes (Supplementary Fig. 2i) as well as in pulmonary vascular smooth muscle cells (Supplementary Figs. 2j and 3g, h).

We also explored whether sr39tk expression exerted effects on the respective target cells. The general appearance and viability of Cre/sr39tk mice (genotype: Cre[tg/+],R26[sr39tk/+] analyzed in this study was normal. In P4/sr39tk mice, platelet counts in peripheral blood were not significantly different from control mice (Supplementary Fig. 4a). In naive CD4/sr39tk mice (genotype: Cre[tg/+],R26[sr39tk/+]), we determined T-cell numbers in the lymph nodes, spleen, and thymus by flow cytometry. Compared with wild-type mice (genotype: Cre[+/+], R26[+/-]), CD4/sr39tk mice had a smaller number of CD3$^+$ lymphocytes, which was primarily due to a smaller fraction of CD4$^+$ T cells (Supplementary Fig. 4b–d). It has been reported that CD4-Cre mice have reduced T-cell numbers, particularly CD4$^+$ T cells in the spleen$^{27}$. However, the CD4-Cre mice (genotype: Cre[tg/+],R26[+/-]) used in our studies showed T-cell numbers similar to wild-type mice, except for a slightly lower number of CD8$^+$ T cells in the thymus that was statistically significant (Supplementary Fig. 4b–d). Thus, the reduced number of T cells we observed in CD4/sr39tk mice was apparently mainly caused by expression of sr39tk and not by expression of Cre recombinase. The spleen weight of CD4/sr39tk mice was not altered compared with control mice (Supplementary Fig. 4e).

Taken together, these results indicated that the R26-mT/sr39tk mouse line is useful to label a broad spectrum of cell types via crossbreeding to existing tissue-specific Cre lines. Importantly, the expression of the sr39tk reporter gene after Cre-mediated activation was strong enough to enable non-invasive detection of the cell.
population of interest and of previously unknown Cre activity in other cell types, via non-invasive PET imaging in vivo. Next, we evaluated the suitability of the R26-mT/sr39tk reporter mouse line for longitudinal cell tracking in two clinically relevant disease models.

T-cell homing during inflammation. To monitor T-cell homing during inflammation, we used a mouse model of allergic contact dermatitis, one of the most frequent inflammatory skin diseases. It is characterized by a T-cell-mediated hypersensitivity reaction of the skin and also studied as a paradigm for autoimmune disorders, antiviral and antitumor immunity. A cutaneous delayed-type hypersensitivity reaction (DTHR) was induced in mice by repetitive application of 2,4,6-trinitrochlorobenzene (TNCB) at day 0. Then, we elicited a transfer of TNCB from the left to the right ear, thereby, inducing a strong systemic immune response in the experimental animals (Fig. 3b). Compared with baseline on day 6, [18F]FHBG uptake into the TNCB-challenged left ears of sr39tk+ mice was 6-fold higher in each animal on day 13 and then returned to a lower level on day 20 (Fig. 3b right), in line with reduced inflammation and ear thickness 8 days after the third TNCB-challenge (Supplementary Fig. 5a). In contrast, [18F]FHBG uptake into the non-challenged right ears of sr39tk+ mice or into the ears of sr39tk− animals remained at a low level over the entire time course (Fig. 3b right). PET imaging of the spleen, lung and liver did not show significant changes in tracer uptake over time in these organs, indicating the absence of a strong systemic immune response in the experimental animals (Supplementary Fig. 5b–d). Autoradiography of the ears on day 20 confirmed strong [18F]FHBG uptake into the TNCB-challenged left ears of sr39tk+ mice (Fig. 3c). Autoradiography detected elevated tracer uptake also in the non-challenged right ears of sr39tk+ mice, in particular in one of the three sr39tk− animals analyzed (Fig. 3c). This was likely due to scratching and transfer of TNCB from the left to the right ear, thereby, inducing inflammation also in the “non-challenged” right ear. The data obtained in vivo by PET imaging and ex vivo by autoradiography showed a good correlation (Supplementary Fig. 5e). We can exclude that the increased [18F]FHBG uptake in TNCB-
challenged ears of sr39tk+ mice was the consequence of inflammation-induced increases in perfusion or vascular permeability (Supplementary Fig. 5a) as we observed no [18F]FHBG uptake in repetitively TNCB-challenged and, thus, strongly inflamed ears of Cre−, sr39tk− control animals (Fig. 4b, c). In sum, our data obtained with CD4/sr39tk mice in the DTHR inflammation model demonstrated that the novel PET reporter transgene allows non-invasive in vivo tracking of endogenous T cells longitudinally over several weeks in mice.

**Cardiomyocyte viability after MI.** As a second clinically relevant disease model, we performed longitudinal PET imaging of cardiomyocytes after MI in Myh6i/sr39tk mice. Myh6i mice express the tamoxifen-inducible CreER12 recombinase under control of the cardiomyocyte-specific Myh6 promoter30. To activate sr39tk expression specifically in cardiomyocytes of adult mice, 17-week-old mice received 1 mg tamoxifen per day for 5 days by intraperitoneal injection. Four weeks later, MI was induced by 60 min temporary ligation (ischemia/reperfusion, I/R group) or permanent ligation (Lig group) of the left anterior descending coronary artery (LAD). Control animals underwent surgery without LAD ligation (Sham group). The study protocol is depicted in Fig. 5a. In week 1, 2 and 3 after MI, we performed [18F]FHBG-PET imaging to monitor viable cardiomyocytes.

![Diagram](image-url)
the same animals, glucose uptake into the heart was detected by 2-[^18F]fluoro-2-deoxy-D-glucose ([^18F]FDG)-PET imaging in week 1 and 2 after MI. To suppress [^18F]FDG uptake into cardiomyocytes and allow imaging of post-infarct inflammation, we used ketamine and xylazine for anesthesia. With this protocol it is possible to preferentially detect non-cardiomyocytes that take up [^18F]FDG, such as immune cells (neutrophils, macrophages, etc.) known to accumulate in the post-ischemic myocardium 31, 32.

To analyze regional differences in tracer uptake in sham-operated and infarcted hearts, we created polar maps (PMs) of the left ventricle. Representative PET images and corresponding PMs are shown in Fig. 5b (for an extended presentation of PET data, see Supplementary Fig. 6). As expected, sham-operated Myh6i/sr39tk mice showed strong and uniform [^18F]FHBG uptake into the myocardium, whereas [^18F]FDG uptake was low (Fig. 5b upper).

Infarcted hearts of the I/R group (Fig. 5b middle) and Lig group (Fig. 5b lower) could be well imaged by detection of viable cardiomyocytes with [^18F]FHBG-PET, with the respective infarcted area spared. [^18F]FHBG-PET signals appeared stable over the whole time course of ≈3 weeks after MI. Compared with remote myocardium, [^18F]FDG uptake into the infarct zone appeared to be increased after MI, presumably due to uptake by infiltrating immune cells. In contrast to the results with [^18F]FHBG-PET the [^18F]FDG-PET signals in infarcted hearts appeared to be more variable over time, and in mice of the I/R group [^18F]FDG uptake was clearly present in the infarcted regions spared by [^18F]FHBG (Fig. 5b).

Quantification of tracer uptake into individual segments of the left ventricle confirmed differences between [^18F]FHBG-PET and [^18F]FDG-PET signals (for an illustration of the segmentation model, see Supplementary Fig. 7a). The infarcted area was defined as segments with a reduction of [^18F]FHBG uptake to <50% of maximal uptake in the same heart. The number of infarcted segments was similar in the I/R group and the Lig group (Supplementary Fig. 7b). Uptake of [^18F]FHBG into the whole left ventricle (infarcted and non-infarcted segments) as well as into the infarcted area alone was stable over 18 days after MI (Supplementary Fig. 7c left, d left). In contrast, uptake of [^18F]FDG into the whole left ventricle as well as infarcted area was higher at 5 days than at 14 days after MI, particularly in the I/R group (Supplementary Fig. 7c right, d right). In both the I/R and Lig group, [^18F]FHBG uptake into the infarcted area was consistently reduced by 50–60% compared to the non-infarcted area of the left ventricle (Supplementary Fig. 7c left). [^18F]FDG uptake into infarcted areas in the Lig group was reduced by ≈25%, whereas infarcted areas from mice in the I/R group showed similar or even slightly higher [^18F]FDG uptake than non-infarcted myocardium (Supplementary Fig. 7c right). Some Myh6i/sr39tk animals in this study also carried the R26-lacZ Cre reporter transgene. This enabled us to correlate in vivo

Fig. 5 Longitudinal [^18F]FHBG and [^18F]FDG PET study in Myh6i/sr39tk mice with myocardial infarction (MI). a Expression of sr39tk was induced in cardiomyocytes of 11 Myh6i/sr39tk mice (genotype: Myh6i-Cre(+/−), R26(sr39tk/+)) by intraperitoneal injection of 1 mg tamoxifen for 5 consecutive days starting 4 weeks before surgery. MI was caused on day 1 (d1) by 60-min temporary ligation (ischemia/reperfusion, I/R) or on day 2 by permanent ligation (Lig) of the left anterior descending coronary artery in three to five animals per group. Two animals underwent surgery without ligation (Sham). All mice underwent [^18F]FHBG-PET on day 4, 13 and 18, and [^18F]FDG-PET on day 5 and 14. b Representative PET images of the heart (HLA, horizontal long axis; SA, short axis; VLA, vertical long axis) and corresponding polar maps (PMs) of the left ventricle of individual mice over the whole time course of the study (for an extended presentation of PET images, see Supplementary Fig. 6). PMs provide an overview of myocardial tracer uptake and were segmented for further regional quantification (see Supplementary Fig. 7). Nonspecific signals were derived from bone (*). PET images were normalized to injected dose of the respective tracer, PMs were normalized to maximal tracer uptake for each tracer, animal and image acquisition. c Some Myh6i/sr39tk mice of this study carried also the R26-lacZ Cre reporter transgene. A representative example of a mouse with permanent ligation is shown. After in vivo [^18F]FHBG-PET imaging (left, nonspecific signals from bone are indicated by *) and autoradiography of a 20-µm short-axis cryosection of the heart (middle) on day 18, β-galactosidase activity was detected in the same section via X-Gal staining (right, counterstain with hematoxylin and eosin). Red outlines demonstrate the correlation between loss of [^18F]FHBG uptake and loss of β-galactosidase activity in the infarcted region (open arrowheads). High-magnification image shows the border region between healthy and infarcted tissue at single-cell resolution (enlarged from overview picture; scale bar: 250 µm). See also Supplementary Figs 6 and 7.
[18F]FHBG-PET imaging and ex vivo [18F]FHBG-autoradiography with β-galactosidase activity in identical heart sections. We observed that loss of [18F]FHBG uptake correlated well with loss of β-galactosidase activity (Fig. 5c). In sum, these experiments showed the feasibility of longitudinal [18F]FHBG-PET imaging using our cardiomyocyte-specific sr39tk reporter mice to monitor cardiomyocyte viability after MI and to characterize infarcts in detail, particularly when [18F]FHBG- and [18F]FDG-PET are combined to image cardiomyocytes and immune cells, respectively.

Discussion

In this study, we have established a modular Cre/lox-based system for non-invasive labeling, tracking and quantification of distinct cell populations in mice. This system relies on stable expression of the sr39tk PET reporter in the cells of interest as well as their progeny. In addition to enabling in vivo cell tracking at the whole-body level, our approach has several advantages over cell-tracking methods that are based on direct cell labeling or expression of a reporter transgene driven by a cell-type-specific promoter. As the sr39tk transgene is integrated into the genome, it permits stable cell labeling that is passed on to all progeny cells. Initially, expression of sr39tk is silenced, but it can be activated in the cell type of interest by crossbreeding with an appropriate cell-type-specific Cre mouse line. Once activated, sr39tk expression is driven by the ubiquitous CAG promoter, rendering it independent of subsequent changes of cell differentiation and potential silencing of tissue-specific promoters. Furthermore, no ex vivo labeling procedures are required, i.e., the cell population of interest is labeled in situ in its physiological environment.

As a proof of concept, we labeled and visualized various cell types by PET imaging and we validated our new mouse model for longitudinal non-invasive cell tracking in two clinically relevant disease models. In Ptf1/sr39tk, CD4/sr39tk or Myh6/sr39tk mice, we were able to detect platelets, T cells or cardiomyocytes, respectively, by [18F]FHBG-PET imaging in vivo. In general, expression of sr39tk did not cause gross abnormalities in the number and/or function of the target cells. We noted that the number of CD4+ T cells was reduced in CD4/sr39tk mice as compared with control mice, but the TNCB-specific response of sr39tk-expressing T cells in the context of our DTHR model was apparently not compromised, as the extent of ear swelling in CD4/sr39tk mice was similar to control mice not expressing sr39tk. The reason for the lower T-cell number in CD4/sr39tk mice is not clear. It is unlikely that it was caused by the potential immunogenicity of the sr39tk protein, because CD4/sr39tk mice express the protein permanently and should, therefore, not mount an immune response against it.

Platelets, T cells and cardiomyocytes could be visualized in vivo in anesthetized mice and specific [18F]FHBG uptake in these cells was confirmed by ex vivo analyses. In few cases, in vivo detection of the respective target cells was compromised by nonspecific accumulation of radioactivity and/or unexpected Cre activity in some tissues. For instance, it was difficult to detect T cells in distinct lymph nodes and the thymus of CD4/sr39tk mice in vivo. Visualization of lymph nodes was impeded by background radioactivity in the bone and gastrointestinal tract, whereas the thymus was masked by [18F]FHBG accumulation in the heart and lungs. The latter was due to previously unknown activity of the CD4-Cre transgene in non-lymphocyte cells of heart and lung. The problem of ectopic Cre activity can be solved by using Cre lines with alternative promoters to drive Cre expression. The current limitation in quantifying T cells in lymph nodes could be overcome by increasing the purity of the [18F]FHBG preparation, which was 82–92% in the present study, thereby reducing the amount of free [18F]fluoride, which accumulates in the bone. Background radioactivity in the gastrointestinal tract could be reduced by increasing [18F]FHBG elimination via the intestine or by using alternative sr39tk substrates with faster clearance such as [18F]FEA34, 35. In addition, the use of thymidine kinase substrates carrying [124I] as longer-lived PET isotope has been described35, 36. With [124I]-labeled radiotracers, PET imaging can be performed much later after tracer injection than with short-lived [18F]-labeled tracers, thereby allowing more ‘non-trapped’ tracer to be eliminated before image acquisition. Another approach to reduce background signals could be the use of alternative Cre reporter genes such as the human or rat sodium iodide symporter. However, the respective tracer, iodine, may show the problem of insufficient intracellular retention due to iodine efflux37.

Detailed knowledge of the specificity of Cre recombination is not only important for cell tracking experiments as described in the present study, but also when Cre mice are used to generate tissue-specific gene knockouts. Published characterization data for Cre strains are often limited to a few specific tissues that were studied in the context of a focused research question. However, it is increasingly recognized that any given transgenic Cre line may display recombination activity beyond the intended tissue or cell type. Therefore, careful characterization of Cre mouse lines is warranted38. The R26-mT/sr39tk reporter mouse provides the possibility for recombination profiling of transgenic Cre mice on a whole-body scale using PET imaging. This novel approach complements existing strategies for comprehensive Cre strain characterization that are based on post-mortem analyses of conventional LacZ Cre reporter mice (http://www.creportal.org)38. Indeed, using our sr39tk PET reporter mice for whole-body imaging combined with the LacZ Cre reporter for subsequent post-mortem analyses of tissue sections, we have identified several previously unreported activities of commonly used Cre strains. Ectopic activity was detected in CD4-Cre mice in smooth muscle cells of myocardial blood vessels as well as in alveolar macrophages and bronchial epithelial cells of the lung, and in Myh6-Cre mice in the lung vasculature.

Among the most exciting applications of our novel sr39tk PET reporter mouse are longitudinal cell tracking studies in the context of health, disease and therapy. For example, tracking of T lymphocytes on the whole-body level can improve our understanding of immune responses to infections and malignancies or during immunotherapy. Diverse procedures have been developed to label T cells in vitro for subsequent PET imaging in mice and humans39–41. However, these experiments are often limited by label dilution and artificial signal loss caused by the proliferation of T cells in the course of an immune response42. In CD4/sr39tk mice we were able, without the need for in vitro labelling, to follow the homing of endogenous CD4+ T lymphocytes to sites of TNCB-specific tissue inflammation over several weeks.

In another clinically relevant disease model, we used Myh6i/sr39tk mice to monitor cardiomyocyte viability after MI. In both preclinical and clinical studies, [18F]FDG is often used for this purpose. However, [18F]FDG reports cellular glucose uptake and metabolism, which are subject to complex regulation and alterations under pathophysiological conditions such as ischemia33. Moreover, uptake of [18F]FDG is not cell-type specific. In addition to cardiomyocytes, other cells in the myocardium may accumulate [18F]FDG, in particular immune cells in the context of post-infarct inflammation31, 32. For these reasons, detection of sr39tk-labeled cardiomyocytes with [18F]FHBG appears to be a more robust approach than [18F]FDG imaging, to specifically assess cardiomyocyte viability in animal models of cardiac disorders. Thus, we sought to use [18F]FHBG-PET for specific detection of cardiomyocytes and [18F]FDG under conditions that...
favor its uptake into immune cells over cardiomyocytes for PET imaging of post-infarct inflammation. Sr39k or related PET reporters have previously been expressed in rodent cardiomyocytes using adenoviral approaches, but expression was limited to the adenovirus-infected region and began to vanish some days after virus administration. In contrast, in Myh6/sr39k mice we observed uniform and stable sr39k expression in the entire myocardium, which allowed longitudinal tracking of cardiomyocyte viability in sub-regions of the heart after MI. The spatial profile and relative amount of [18F]FHBG uptake after MI induction remained constant over the whole 3-week period of our study. The combination of PET imaging with [18F]FHBG and [18F]FDG enabled us to characterize infarcts in detail by visualization of viable cardiomyocytes and post-infarct inflammation, respectively. The fact that permanent LAD ligation results in almost complete loss of perfusion of the infarcted zone might complicate the interpretation of tracer uptake in this region after permanent LAD ligation. However, after I/R injury, perfusion is maintained and thus it appears that the stable reduction of [18F]FHBG uptake in the infarcted region is indeed due to cardiomyocyte death rather than loss of perfusion. In contrast, [18F]FDG uptake after I/R injury was initially increased in the infarcted region and was more variable over time, presumably due to inflammatory processes within the infarcted region and [18F]FDG uptake into immune cells.

Taken together, this study demonstrates the suitability of our novel sr39k PET reporter mouse for non-invasive visualization, quantification and tracking of specific cell populations in mice. The binary nature of the system permits labeling of a broad spectrum of cell types by crossbreeding the sr39k reporter line with different Cre strains, hundreds of which are available for targeting basically any cell type of interest (http://www.creportal.org). It is also possible to combine the sr39k PET reporter allele with other Cre-switchable reporter transgenes. This enables, for instance, combined in vivo imaging of cells by PET and other modalities (e.g., fluorescence, bioluminescence) or validation of PET data by post-mortem histochemical cell detection by X-Gal staining of β-galactosidase activity. Moreover, combination of the sr39k PET reporter with Cre-sensitive conditional knockout alleles allows in vivo-tracking of cell populations that lack a protein of interest. Previous methods for cell tracking with PET were based on direct in vivo-tracking of cell populations that lack a protein of interest. For example, to correlate [18F]FDG uptake with expression of β-galactosidase encoded by the R26-lacZ reporter protein irrespective of cell phenotype and potential silencing of a tissue-specific promoter. Our Cre/lox-based PET reporter approach has one major advantage over these methods, in that it permits in vivo labeling of essentially any cell type of interest followed by stable/inheritable expression of the PET reporter protein irrespective of cell phenotype and potential silencing of a tissue-specific promoter. The latter property might be particularly useful to keep track of initially labeled cells after dedifferentiation or transdifferentiation, for instance, during vascular remodeling or cell therapy. If tamoxifen-inducible Cre recombinases such as CreER<sup>T2</sup> are used for cell labeling, it should be considered that only cells will be labeled that expressed the recombinase during the tamoxifen pulse and that these cells might later be “diluted” by non-labeled cells originating from a pool of CreER<sup>T2</sup>-negative progenitor cells. For instance, if in our MI model newly formed cardiomyocytes were derived from sr39k–progenitor cells, then these cardiomyocytes would not take up [18F]FHBG, and cell viability would be underestimated by [18F]FDG-PET. In general, labeling of rapidly proliferating cell populations by tamoxifen-inducible CreER<sup>T2</sup> may be mosaic and, therefore, non-recombined cells may dilute the reporter signal when they proliferate. This problem can be addressed by using a non-inducible Cre line, for instance, the Myh6-Cre line for efficient labeling of cardiomyocytes.

We foresee many applications of our sr39k PET reporter mice in preclinical research. In combination with MRI or other PET tracers (as shown in the present study), this mouse line will improve our understanding of mammalian (patho-)biology associated with migration, accumulation, death, or survival of distinct cell populations. These processes are of fundamental importance in clinical conditions such as inflammation, diabetes, atherosclerosis, thrombosis, MI, stroke and tumorigenesis. Our method will also be useful to elucidate endogenous mechanisms of tissue degeneration and regeneration as well as effects of therapeutic interventions. Cells derived from sr39k PET reporter ES cells or mice can aid the development of effective cell-based therapies, which requires monitoring of the location, distribution and long-term viability of the transplanted cells in a non-invasive manner.

In this context, sr39k can be used not only as a PET reporter, but also as a suicide gene enabling the elimination of therapeutic cells by ganciclovir treatment, if they are causing severe adverse effects. We anticipate that the Cre-switchable sr39k PET reporter mice will be broadly applicable to address complex biological questions in vivo and, compared to invasive cell-tracking methods, enable preclinical research with fewer animals and complementary informative value.

**Methods**

**Experimental animals.** All animal experiments were performed at the University of Tübingen and approved by the local authority (Regierungspräsidium Tübingen, PC 1/08 and IB 1/13). Mice were housed in a barrier-free or individually-ventilated-cage mouse facility at 19–22 °C and 40–60% humidity in a 12/12 h light/dark cycle with free access to standard rodent chow and tap water. R26-mT/sr39k PET reporter mice (B6;129-Gt(Rosa)26Soer tm2(ACTB-tdTomato,-sr39kFlpr)) were generated in this study and had a mixed 129 Sv/C57BL6N genetic background. R26-lacZ Cre reporter mice (B6;129-Gt(Rosa)26Soer tm1(lacZ))<sub>10</sub> were on a C57BL/6N background. Cre mice were obtained from the following sources: CD4-Cre (Tg(Cd4-cre)24; from Andreas Friebre (Universität Würzburg, Würzburg, Germany). All Cre lines were maintained on a C57BL/6N background.

The generate experimental animals, male Cre<sup>tg/+</sup>;R26<sup/+</sup> mice were mated with female Cre<sup>tg/+</sup>;R26<sup>sr39k/+</sup> mice; “+” denotes the wild-type allele. To correlate [18F]FDG uptake with expression of β-galactosidase encoded by the R26-lacZ reporter protein, male Cre<sup>tg/+</sup>;R26<sup>lacZ</sup> mice were mated with female Cre<sup>tg/+</sup>;R26<sup>sr39k/+</sup> mice. Experimental animals were males and females with an age between 9 and 42 weeks (for further details, see Supplementary Table 1). The sr39k-expressing mice (designated Cre/sr39k or sr39k<sup>+</sup>) had the genotype Cre<sup>tg/+</sup>;R26<sup>sr39k</sup>−/−; animals that expressed sr39k<sup>−/−</sup> and β-galactosidase (designated Cre/sr39k<sup>−lacZ</sup>) had the genotype Cre<sup>tg</sup>−/−;R26<sup>sr39k</sup>−/−; lactZ animals were generated by Southern blot analysis of EcoRV-digested genomic DNA with a probe that binds to the integration site. R26<sup>sr39k</sup>−lacZ expressers (designated Cre/sr39k<sup>−lacZ</sup>) had the genotype Cre<sup>tg</sup>−/−;R26<sup>sr39k</sup>−/−; lacZ<sup>−/−</sup> and β-galactosidase-expressing animals (designated Cre/lacZ; genotype: Cre<sup>tg</sup>−/−;R26<sup>lacZ</sup>−/−) and respective Cre-negative control animals (genotype: Cre<sup>−/−</sup>/lacZ<sup>−/−</sup>).

**Generation of R26-mT/sr39k mice.** The gene targeting vector pROSA26-mT/sr39k was used to integrate the CAG promoter, a loxP-flanked expression cassette for membrane-targeted tandem-dimer red fluorescent protein (mT) into R26<sup>mT</sup>/− ES cells. mT encoded here is flanked by loxP sites and thus can be inactivated by Cre-mediated excision. The selection resistance cassette into the murine R26 locus (Supplementary Fig. 1A). To generate pROSA26-mT/sr39k, the coding sequence of membrane-targeted green fluorescent protein (mG) in pROSA26-mT<sup>mC</sup> (Addgene plasmid 17787) was replaced by the sr39k<sup>−</sup>encoding sequence from pmG-mr39k (provided by Sam Gambhir, Stanford University, CA, USA). Gene targeting of R26<sup>mG</sup>/− ES cells was achieved by homologous recombination, as described<sup>19, 48</sup>. In brief, 60 µg of Accl-linearized pROSA26-mT/sr39k were electroporated into R1 ES cells<sup>49</sup>. After 8 days of selection with 320 µg/mL G418 (GIBCO, Life Technologies, Darmstadt, Germany), 200 clones were isolated and expanded. Fourteen correctly targeted ES cell clones carrying the R26-mT/sr39k knock-in allele were identified by Southern blot analysis of EcoRV-digested genomic DNA with a probe that binds to the integration site<sup>46</sup>. R26-mT/sr39k mice were generated by injection of ES cells into 3.5 dpc C57BL/6N blastocysts. Male chimeras were mated with C57BL/6N females to obtain heterozygous R26-mT/sr39k mice (B6;129-Gt(Rosa)26Soer tm2(ACTB-tdTomato,-sr39kFlpr)) on a C57BL/6N genetic background. Germline transmission of the modified R26 allele was verified by Southern blot analysis of tail DNA. Heterozygous male R26-mT/sr39k mice showed a severely reduced reproductive rate.
(no offspring from >10 different heterozygous R26-mT/sr39tk males). Heterozygous female R26-mT/sr39tk mice were fertile and backcrossed to C57BL/6N animals for three to eight times before experimental animals were generated.

**Genotyping.** PCR-based genotyping of ear biopsies was done for R26-mT/sr39tk mice with primers ROSA10 (5′-CTCTCTGCTCTCCTGCTTCT-3′), ROSA11 (5′-CGAGGGGCGATCAAAGGATAA-3′) and ROSA4 (5′-CTAATGGGGGCTGGTCTT-3′) ([Supplementary Fig. 1a](#supplementary), and for R26-lacZ mice with ROSA10, ROSA11 and RF127 (5′-GACAGGCAGGCCTTCTCTGAA-3′) [Supplementary Fig. 1c](#supplementary), which amplify a 400-bp fragment of the Cre transgene. To detect the P4i-Cre and Myh6-CreR2T2 transgenes, we used primers EcIcre1 (5′-GACAGGGGCGATCAAAGGATAA-3′) and EcIcre2 (5′-CTCTCTGCTCTCCTGCTTCTG-3′), which amplify a 522-bp fragment of the Cre transgene. The PCR primers specific for the Cre transgene as described in the respective original publications 22-24, 30.

**Generation and analysis of ES cells with activated sr39tk expression.** R26-mT/sr39tk ES cells carrying the Cre-activatable L2 allele were electroporated with the Cre-expression plasmid pLc-Cre10 to generate ES cells with an excised mT cassette and activated sr39tk expression (L1 allele) ([Supplementary Fig. 1a](#supplementary)). ES cell clones carrying the L1 allele were identified by a combination of Southern blot analysis, fluorescence microscopy to detect loss of expression of GFP, and Southern blotting to show that the integrity of the Cre transgene was not lost. To confirm that the Cre transgene was not lost, ES cells were subjected to PCR using primers specific for the Cre transgene as described in the respective original publications 22-24, 30.

**Platelet counts were determined in whole blood drawn from the retroorbital plexus of isoflurane-anesthetized animals into 300 µL acid citrate-dextrose buffer. Platelet numbers were determined with an automated blood analyzer (Sysmex Se 9000, Kobe, Japan).**

**CuteHar Duro model.** Delayed-type hypersensitivity reactions (DTHRs) were induced with 2,4,6-trinitrochlorobenzene (TNCB) as described previously 25. Briefly, mice were sensitized by application of 80 µL of 5% TNCB dissolved in a 4:1 mixture of acetone and Miglyol 812 (Sigma-Aldrich, St. Louis, Germany) to the shaved abdomen. Seven, 10 and 12 days later, mice were challenged with 20 µL of 1% TNCB dissolved in a 1:9 mixture of acetone and Miglyol 812 on both sides of the left ear to elicit a TNCB-specific contact hypersensitivity reaction. The degree of inflammation was assessed through measurement of ear thickness with a digital micrometer before the 12 h TNCB challenge, and then every 3 days.

**Mi model.** Mi was performed by surgical ligation of the LAD coronary artery. Briefly, mice were anesthetized with 5 mg/kg intraperitoneal midazolam, 0.5 mg/kg intraperitoneal medetomidin and 0.05 mg/kg subcutaneous fentanyl. After ooro-tracheal intubation and ventilation, the thoracic cavity was surgically exposed. For permanent ligation, the LAD was ligated with a non-resorbable 8-0 filament. I/R injury was induced by ligation of the LAD for 60 min with the aid of a polyethylene tube. Ischaemia and reperfusion were confirmed by discolouration and akinesia or recoloration, respectively, of the ischemic region. Sham treatment was performed without ligation of the filament. After closing of the access site, anesthesia was antagonized by injection of atipamezol (2.5 mg/kg 31) and flumazenil (0.5 mg/kg 32), and animals were monitored until recovery. Buprenorphine (0.05 mg/kg 33) was injected subcutaneously for analgesia.

**PET tracer synthesis.** Tracers were synthesized by the Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center Tübingen. [18F]Fluoride was produced at the PETtrace cyclotron (General Electric Healthcare, Uppsala, Sweden) using [18O]water (Rotem, Leipzig, Germany) and the 18O(p,e) 17 nuclear reaction. [18F]FHBG was synthesized according to previously described procedures 26, 34 with some modifications. [18F]Fluoride was transferred to an automated synthesis module (TRACERlab FX-FN, GE Healthcare, Liège, Belgium) and first adsorbed on an ion exchange cartridge (PEP-Pak light, Accell Plus QMA, Waters, USA) preconditioned with 10 mL of 1 N aqueous NaHCO3 and 10 mL H2O. [18F]Fluoride was eluted and flushed into the reaction vial with a mixture of deionized water and injection volume of 3.5 µL of 0.4 N NaHCO3 and 15 mg (40 µmol) Kryptofix 2.2.2. dissolved. The solution was dried under vacuum at 60 °C for 5 min and afterwards at 120 °C for additional 5 min. Labeling was carried out using 4 mg of the precursor Tosyl-FHBG (ABX, Radeberg, Germany) in 1 mL dimethyl sulfoxide under stirring at 120 °C within 5 min. For neutralization of the reaction mixture, 0.4 mL of 2 N aqueous NaOH was added. Unreacted [18F]Fluoride was removed by passing the reaction solution through an Al2O3-cartridge (PEP-Pak light, Alumina N, Waters) preconditioned with 10 µL water. Afterwards, the solution was flushed with 0.5 µL of water, which was also passed through the Al2O3-cartridge. The combined fractions were injected onto the high-performance liquid chromatography (HPLC) column (Phenomenex Luna column C18/2, 50 x 10 mm; 5 µm) for separation. A mixture of ethyl alcohol/50 mM Na2HPO4 (5/95, v/v) was used as eluent. Retention time of the product was 18–22 min at a flow rate of 4 mL/min, detected by UV (254 nm) and radio detection. The THF was adjusted by adding 0.04 N NaHCO3. Finally, the product was sterile filtered through a 0.22-µm filter. Overall synthesis time was 60 min. Volume of the product was in the range of 6–10 mL, activity of the batches was 1.9–3.9 GBq. Radiochemical purity was determined via thin layer chromatography/phosphor imager analysis and HPLC and was 82–92% with both methods. Specific activity was >100 GBq/µmol at the end of synthesis. [18F]FDBG was synthesized in a TRACERlab MXFDG synthesizer (GE Healthcare) using previously established method 35 and mannose triflate (ABX) as a precursor. Quality control was performed in accordance with European pharmacopoeia quality guidelines. The radiochemical purity as determined by thin layer chromatography was >95%.

**In vivo PET imaging and ex vivo analysis of tracer uptake.** Animals were imaged using dedicated Inveon small animal PET scanners (Siemens Preclinical Solutions, Knoxville, TN, USA) yielding a spatial resolution of ±1.3 mm in the reconstructed images 36. For [18F]FHBG imaging, animals were anesthetized for 5–10 min with 1.5% isoflurane in pure oxygen and injected with tracer into the tail vein, and 180 min after tracer injection for conscious uptake, animals were anesthetized with 1.5% isoflurane in pure oxygen and PET acquisition was performed for 20 min. For [18F]FDBG imaging, ketamine (100 mg/kg body weight) and xylazine (10 mg/kg body weight) were used for anesthesia. Sixty minutes after tracer injection into the tail vein and unconscious uptake on a heating blanket, a 10 min PET acquisition was performed. All PET data were reconstructed with a default ordered subsets expectation maximization algorithm.

**MR imaging was performed on dedicated 7T small animal MR tomographs (Bruker Biospin MRI and CliniScan, Bruker, Ettlingen, Germany) with fiducial...
markers containing [3H] activity for subsequent image fusion. A T2-weighted three-dimensional space sequence (TE/TR 205/3000 ms, matrix of 161 × 256, slice thickness 0.22 mm) was used to obtain morphological information. For data analysis, PET and MRI images were fused, normalized to each other and analyzed using Inveon Research Workspace software (Siemens Preclinical Solutions) or Amira. Then, analyze tracer uptake into selected organs, three-dimensional regions of interest (ROIs) were drawn. When available, co-registered MR images were used to define ROIs; otherwise, PET tracer uptake patterns were used for ROI definition. To analyze regional uptake into the myocardium, 17-segment PMs of cardiac PET images were created using PMOD software (PMOD Technologies Ltd, Zurich, Switzerland). Uptake of [18F]FHBG and [18F]FDG are reported as percent injected dose (ID) per cubic centimeter (%ID/c.cm.).

To determine [3H]HFBG uptake in isolated organs and tissue slices, animals were killed and dissected tissues were subjected to biodistribution analysis or autoradiography. To analyze tracer biodistribution, organ radioactivity was measured in a γ-counter (Wallac: 1470 WIZARD). The fraction of injected tracer dose per gram tissue (ID/g) was calculated by normalizing decay-corrected counts on ID and sample wet weight. For autoradiography, organs were embedded and snap-frozen in O.C.T. TissueTek Compound (Sakura Finetek, Torrance, CA, USA). Organs were cut into 20-μm sections using a CM1850 cryostat (Leica Microsystems, Wetzlar, Germany). Dry sections were placed on a phosphor screen. After 24 h, the screen was read on a STORM Phosphor-Imager (Molecular Dynamics, Sunnyvale, CA, USA). Images were analyzed using Inveon Research Workplace software (Siemens Preclinical Solutions), or Amira, and morphological imaging was performed with ImageJ (National Institute of Health, Bethesda, MD, USA).

**p < 0.01 and ***p < 0.001, respectively. Normal distribution of data was not tested. Homogeneity of variance between groups was tested using the Brown–Forsythe test.**

**Data availability.** All relevant data are available upon request from the corresponding author.

Received: 11 December 2016 Accepted: 3 July 2017
Published online: 05 September 2017

**References**

1. Kircher, M. F., Gambhir, S. S. & Grimm, J. Noninvasive cell-tracking methods. Nat. Rev. Clin. Oncol. 8, 677–688 (2011).
2. Leuscher, F. & Nahrendorf, M. Molecular imaging of coronary atherosclerosis and myocardial infarction: considerations for the bench and perspectives for the clinic. Circ. Res. 108, 593–606 (2011).
3. Naumova, A. V., Modo, M., Moore, A., Murry, C. E. & Frank, J. A. Clinical imaging in regenerative medicine. Nat. Biotechnol. 32, 804–818 (2014).
4. Nguyen, P. K., Riegler, J. & Wu, J. C. Stem cell imaging: from bench to bedside. Cell Stem Cell 14, 431–444 (2014).
5. Weisleder, R., Schweiger, M. C., Gambhir, S. S. & Hricak, H. Imaging approaches to optimize molecular therapies. Sci. Transl. Med. 8, 355ps16 (2016).
6. Branda, C. S. & Dymecki, S. M. Talking about a revolution: the impact of site-specific recombinases on genetics analyses in mice. Dev. Cell 6, 7–28 (2004).
7. Feil, R. Conditional somatic mutagenesis in the mouse using site-specific recombinases. Handb. Exp. Pharmacol. 178, 3–28 (2007).
8. Joynar, A. L. & Zervas, M. Genetic inducible fate mapping in mouse: establishing genetic lineages and defining genetic neuroanatomy in the nervous system. Dev. Dyn. 235, 2376–2385 (2006).
9. Feil, S., Krauss, J., Thunemann, M. & Feil, R. Genetic inducible fate mapping in adult mice using tamoxifen-dependent Cre recombinases. Methods Mol. Biol. 1194, 113–139 (2014).
10. Soriano, P. Generalized IacZ expression with the ROSA26Cre reporter strain. Nat. Genet. 21, 70–71 (1999).
11. Judenhofer, M. S. et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. J. Magn. Reson. Imaging 17, 593–605 (2003).
12. Massoud, T. F. & Gambhir, S. S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 17, 545–580 (2003).
13. Yaghoubi, S. S., Campbell, D. O., Radu, C. G. & Czernin, J. Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications. Theranostics 2, 374–391 (2012).
14. Bathiany, E., Kokoris, M. S. & Sabo, P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-activated tumor cell killing. Cancer Res. 61, 3022–3026 (2001).
15. Gambhir, S. S. et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc. Natl Acad. Sci. USA 97, 2785–2790 (2000).
16. Sundersan, G. et al. MicroPET imaging of Cre-loxP-mediated conditional activation of a herpes simplex virus type 1 thymidine kinase reporter gene. Gene Ther. 11, 609–618 (2004).
17. Chang, G. Y. et al. Positron emission tomography imaging of conditional gene activation in the heart. J. Mol. Cell Cardiol. 43, 18–26 (2007).
18. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-fluorescent Cre reporter mouse. Genesis 45, 593–605 (2007).
19. Thunemann, M. et al. Transgenic mice for cGMP imaging. Circ. Res. 113, 365–371 (2013).
20. al-Shawi, R. et al. The herpes simplex virus type 1 thymidine kinase is expressed in the testes of transgenic mice under the control of a cryptic promoter. Mol. Cell Biol. 11, 4207–4216 (1991).
21. Braun, R. E. et al. Infertility in male transgenic mice: disruption of sperm function by HSV-tk expression in postmeiotic germ cells. Mol. Cell Biol. 14, 459–465 (2008).
22. Tiedt, R., Schombner, T., Hao-Shen, H. & Skoda, R. C. Pf4-Cre transgenic mice for the activation of a herpes simplex virus type 1 thymidine kinase reporter gene. Dev. Cell 304, 651 to 436 (2016).
23. Yu, J. et al. Activation of a herpes simplex virus type 1 thymidine kinase reporter gene. Dev. Cell 22, 365–371 (2013).
24. al-Shawi, R. et al. The herpes simplex virus type 1 thymidine kinase is expressed in the testes of transgenic mice under the control of a cryptic promoter. Mol. Cell Biol. 11, 4207–4216 (1991).
25. Yaghoubi, S. et al. Human pharmacokinetic and dosimetry studies of [(18)F]FBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J. Nucl. Med. 42, 1225–1234 (2001).
26. Alauddin, M. M., Shahinian, A., Gordon, E. M., Bading, J. R. & Conti, P. S. Preclinical evaluation of the penciclovir analog 9-(4-[[18F]fluoro-3-hydroxymethyl]butyl]guanine for in vivo measurement of suicide gene expression with PET. J. Nucl. Med. 42, 1682–1690 (2001).

27. Westendorf, K., Durek, P., Ayew, S., Mashreghi, M. F. & Radbruch, A. Chromosomal localization of the CD4cre transgene in B6.Cg-Tg(Cd4-cre)1Cwi mice. J. Immunol. Methods 436, 54–57 (2016).

28. Goebel, M. D., Good, S. A. & Valdes Hernandez, R. Allergic contact dermatitis. Curr. Dir. Asthma. 10, 1–26 (2008).

29. Pichler, B. J. et al. Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. J. Nucl. Med. 46, 184–189 (2005).

30. Takelji, M. et al. Gl(13)-mediated signaling pathway is required for pressure overload-induced cardiac remodeling and heart failure. Circulation 126, 2272–2282 (2012).

31. Lee, W. W. et al. PET/MRI of inflammation in myocardial infarction. J. Am. Coll. Cardiol. 59, 153–162 (2012).

32. Thackeray, J. T. et al. Targeting post-infarct inflammation by PET imaging: comparison of (68)Ga-citrate and (68)Ga-DOTATATE with (18)F-FDG in a mouse model. Eur. J. Nucl. Med. Mol. Imaging 42, 317–327 (2015).

33. Berger, C., Flowers, M. E., Warren, E. H. & Riddell, S. R. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107, 2294–2302 (2006).

34. Chin, F. T. et al. Semiautomated radiosynthesis and biological evaluation of [18F]EAU: a novel F-18 labeled PET imaging agent for HSV1-tk/sr39tk reporter gene expression. Mol. Imaging Biol. 10, 82–91 (2008).

35. Ruggiero, A. et al. Different strategies for reducing intestinal background radioactivity associated with imaging HSV1-tk expression using established radionucleotide probes. Mol. Imaging 9, 47–58 (2010).

36. Tyuravez, J. G. et al. Comparison of radiolabeled nucleoside probes ([F18]FHBG, and [F18]FHPG) for PET imaging of HSV1-tk gene expression. J. Nucl. Med. 43, 1072–1083 (2002).

37. Haberkorn, U. et al. Transfer of the human NaI symporter gene enhances iodide uptake in hematopoietic cell lines. J. Nucl. Med. 42, 317–325 (2001).

38. Heffner, C. S. et al. Supporting conditional mouse mutagenesis with a comprehensive cre characterization resource. Nat. Commun. 3, 1218 (2012).

39. Dube, P. et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc. Natl Acad. Sci. USA 100, 1232–1237 (2003).

40. Shu, C. J. et al. Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. Int. Immunol. 21, 155–165 (2009).

41. Griessinger, C. M. et al. 64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET. Proc. Natl Acad. Sci. USA 112, 1161–1166 (2015).

42. Nair-Gill, E. D., Shu, C. J., Radu, C. G. & Witte, O. N. Non-invasive imaging of adaptive immunity using positron emission tomography. Immunol. Rev. 221, 214–228 (2008).

43. Peterson, L. R. & Gropler, R. J. Radionuclide imaging of myocardial metabolism. Circ. Cardiovasc. Imaging 3, 211–222 (2010).

44. Wu, J. C., Inubushi, M., Sundaresan, G., Schellert, H. R. & Gambhir, S. S. Positron emission tomography imaging of cardiac reporter gene expression in living rats. Circulation 106, 180–183 (2002).

45. Chen, I. Y. et al. Micro positron emission tomography imaging of cardiac gene expression in rats using biocistronic adenoviral vector-mediated gene delivery. Circulation 109, 1415–1420 (2004).

46. Feil, S. et al. Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circ. Res. 115, 662–667 (2014).

47. Bonini, C. et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719–1724 (1997).

48. Kubandner, S. et al. Temporally controlled somatic mutagenesis in smooth muscle. Genesis 28, 15–22 (2000).

49. Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W. & Roder, J. C. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc. Natl Acad. Sci. USA 90, 8424–8428 (1993).

50. Hor, C., Wurst, W. & Kuhn, R. Conditional brain-specific knockdown of MAPK using Cre/loxP regulated RNA interference. Nucleic Acids Res. 35, e90 (2007).

51. Zong, H., Espinosa, J. S., Su, H. H., Muzumdar, M. D. & Luo, L. Mosaic analysis with double markers in mice. Cell 121, 479–492 (2005).

52. Shimshek, D. E. et al. Codon-improved Cre recombinase (iCre) expression in the mouse. Genesis 32, 19–26 (2002).

53. Gu, H., Zou, Y. R. & Rajewsky, K. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre/loxP-mediated gene targeting. Cell 73, 1155–1164 (1993).

54. Alauddin, M. M. & Conti, P. S. Synthesis and preliminary evaluation of 9-(4-[[18F]fluoro-3-hydroxymethyl]butyl]guanine ([18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET. Nucl. Med. Biol. 25, 175–180 (1998).

55. Hamacher, K., Coenen, H. H. & Stocklin, G. Efficient stereospecific synthesis of no-carrier-added 2-[[18F]fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J. Nucl. Med. 27, 235–238 (1986).

56. Bao, Q., Newport, D., Chen, M., Stout, D. B. & Chatzioannou, A. F. Performance evaluation of the in vivo dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J. Nucl. Med. 50, 401–408 (2009).

57. Loening, A. M. & Gambhir, S. S. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2, 131–137 (2003).

58. Tsuji, Y., Takegawa, M. D. et al. Staged multiphase segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac imaging committee of the council on clinical cardiology of the American heart association. Circulation 105, 539–542 (2002).

Acknowledgements
We thank S. Adone, B. Birk, D. Bukala, M. Harant and N. Altmeier for excellent technical assistance; I. Gonzalez Menendez for help with preparation of figures; M. PoUlido for reading the manuscript; A. Friebe, Stefan Offermanns and A. Waisman for providing Cre mice; S. Gambhir for the sr39tk construct; L. Luo for the pRos26-mTmG plasmid; W.C. Summers for the HSV1-tk antiseraum; and all members of R.F.’s laboratory for critical discussion. This work was supported by the Fund of Science, Deutsche Forschungsgemeinschaft (KFO 274 projects FE 438/8-2, LA 2423/4-2 and LA 2423/7-2, SFB TRR156 project 03), BMBF (grant number 0314013) and the Interdisciplinary Centre for Clinical Studies (IZKF), Core Unit PIX, University of Münster, Münster, Germany.

Author contributions
M.T. performed and analyzed most of the experiments and generated the figures. B.F.S. and Y.L. performed and evaluated PET imaging studies together with M.T. S.F. helped with the generation of R26-mTmGsr39tk mice and performed fluorescence microscopy of organs. B.F.S. and M.K. provided the DTHR model and T-cell analysis. J.V. performed the MI model. M. Golla helped with X-Gal staining of tissues. A.V. contributed to construction of the targeting vector. U.K. and L.Q.-M. did immunohistochemistry. M.O., H.F.L. and M. Gawaz helped with platelet analysis. M.E. and G.R. performed tracer synthesis. M.T., C.M.G., F.L., M.S., M.K., B.J.P. and R.F. contributed to the design of experiments. R.F. oversaw the study. M.T. and R.F. wrote the manuscript. All authors discussed and commented on the manuscript.

Additional information
Supplementary Information accompanies this paper at doi:10.1038/s41467-017-00482-y.

Competing interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://www.nature.com/ reprintsandpermissions/

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.